Coccidioides immitis Spherule - Derived Skin Test Antigen

Trade name: Spherusol

BiologicalapprovedOrphan Drug FDA

Approved

Jul 29, 2011

Coccidioides immitis is a pathogenic fungus that resides in the soil in certain parts of the southwestern United States, northern Mexico, and a few other areas in the Western Hemisphere. — Wikipedia

Clinical trial activity

1 trials · 4 clinical orgs · 3 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started May 1, 2005 (NCT00690092)

Timeline

2000s

  1. Jan 1, 2005

    Nielsen BioSciences, Inc. — Earliest Phase 3 Sponsor(trial)

  2. Dec 19, 2007

    Orphan Drug Designation

2010s

  1. Jul 27, 2011

    Allermed Laboratories — First NDA Organization

  2. Jul 27, 2011

    Allermed Laboratories — NDA Organization

  3. Jul 27, 2011

    Rare Disease Therapeutics — Marketing Organization

  4. Jul 29, 2011

    Earliest FDA Approval

  5. Jul 29, 2011

    Nielsen BioSciences, Inc. — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedJul 29, 2011

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • coccidioides immitis spherule-derived skin test antigen
  • coccidioidin
  • spherusol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00690092Phase 3May 1, 2005Nielsen BioSciences, Inc., Sr Consultants Inc., University of Arizona, University of California, Los Angeles
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Nielsen BioSciences, Inc.For profit1112005
Sr Consultants Inc.For profit1012005
University of ArizonaAcademic/Hospital1012005
University of California, Los AngelesAcademic/Hospital1012005
4 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
Allermed LaboratoriesFor profitNDAJul 27, 2011
Nielsen BioSciences, Inc.For profitNDA2Jul 29, 2011
Rare Disease TherapeuticsFor profitMKTGJul 27, 2011